跳至主要内容
临床试验/NCT00446901
NCT00446901
已完成
不适用

Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression

Wageningen University2 个研究点 分布在 1 个国家目标入组 60 人2007年6月

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Prostatic Neoplasms
发起方
Wageningen University
入组人数
60
试验地点
2
主要终点
selenium levels in prostate tissue
状态
已完成
最后更新
15年前

概览

简要总结

The aim of this study is to determine whether selenium supplementation leads to changes in selenium levels and gene expression profiles in prostate tissue.

详细描述

Rationale: Prostate cancer is a frequently observed malignancy in men, especially in elderly men. Besides diagnosis and treatment, also prevention of prostate cancer is an important point of interest to reduce the incidence and mortality of prostate cancer. Selenium is considered to be a promising chemopreventive agent for prostate cancer. Exact mechanisms of chemoprevention by selenium are not fully understood. However, it is expected that selenium (among other effects) directly affects gene expression in the prostate. Objective: The aim of this study is to get insight into bioavailability of selenium in prostate tissue and changes of gene expression profiles that might be responsible for selenium-induced chemoprevention. To meet this objective, the relationship between dietary selenium intake and changes in gene expression profiles, tissue selenium levels and blood flow in prostate tissue will be examined. Study design: The present study is designed as a double-blind, randomized and placebo-controlled intervention trial. Blood samples, toenails, questionnaires, MR images and surgical specimens will be collected to examine effects of selenium supplementation. Study population: The study population will consist of 60 men, diagnosed with prostate cancer and scheduled for radical prostatectomy. Written informed consent will be obtained from each participant. Intervention: Participants will receive 300 ug selenium / day or a placebo during 5 weeks prior to radical prostatectomy. Selenium will be supplemented in the form of selenized yeast tablets (SelenoPrecise, Pharma Nord). Main study parameters: Levels of selenium in prostate tissue and changes in prostate gene expression profiles of participants supplemented with selenium or placebo, compared before and after the short intervention period, will be considered as the main parameters of the present study. Besides gene expression profiles in prostate tissue, also gene expression profiles of peripheral mononuclear cells (PBMC), levels of selenium in blood and toenails and blood flow and permeability of blood vessels of prostate tissue will be analyzed.

注册库
clinicaltrials.gov
开始日期
2007年6月
结束日期
2011年1月
最后更新
15年前
研究类型
Interventional
研究设计
Parallel
性别
Male

研究者

入排标准

入选标准

  • biopsy proven prostate cancer
  • scheduled for radical prostatectomy

排除标准

  • liver diseases (e.g. hepatitis)
  • kidney diseases
  • inflammatory bowel diseases
  • use of dietary supplements containing selenium
  • adjuvant therapy for prostate cancer (e.g. hormonal therapy, HIFU)
  • previously or concurrent diagnosed with cancer, other than prostate cancer

结局指标

主要结局

selenium levels in prostate tissue

时间窗: after 5 weeks of intervention with selenium or placebo

changes in gene expression profiles in prostate tissue

时间窗: after 5 weeks of intervention with selenium or placebo

次要结局

  • changes in blood flow, vessel permeability and exocrine functionality(after 5 weeks of intervention with selenium or placebo)
  • changes in gene expression profiles in blood cells(after 5 weeks of intervention with selenium or placebo)

研究点 (2)

Loading locations...

相似试验